Respiratory syncytial virus-neutralizing serum antibody titers in infants following palivizumab prophylaxis with an abbreviated dosing regimen

Jennifer Claydon, Amitava Sur, Allison Callejas, Mihoko Ladd, Eddie Kwan, Richard Taylor, Stuart E. Turvey, Alfonso Solimano, Pascal M. Lavoie, Nico Marr

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background Monthly injections of palivizumab during the respiratory syncytial virus (RSV) season in atrisk infants reduces RSV-associated hospitalizations. However, the additive effect of naturally acquired immunity remains unclear. The objective of this study was to assess total neutralizing serum antibodies (NAb) against RSV in at-risk infants who had received an abbreviated course of palivizumab prophylaxis. Methods Serum samples were collected from infants enrolled in the RSV Immunoprophylaxis Program in British Columbia, Canada over 2 consecutive RSV seasons (2013 to 2015). Infants in this program had received an abbreviated course of palivizumab in accordance with the provincial guidelines. Data were compared to adults and infants less than 12 months of age who did not receive palivizumab. Anti-RSV NAb titers were measured using an RSV microneutralization assay. Findings Infants who received palivizumab had anti-RSV NAb titers at the end of the RSV season that persisted beyond what is expected from the pharmacokinetics of palivizumab alone. Moreover, 54% of the control infants who did not receive palivizumab and all tested adults had protective anti-RSV NAb titers.Conclusions Based on our observations, we hypothesize that naturally acquired NAb provide additive protection, which may significantly reduce the need for additional doses of palivizumab in infants at risk of severe RSV infections.

Original languageEnglish
Article numbere0176152
JournalPLoS One
Volume12
Issue number4
DOIs
Publication statusPublished - 1 Apr 2017
Externally publishedYes

Fingerprint

Respiratory Syncytial Viruses
Neutralizing Antibodies
Viruses
neutralization
disease control
viruses
antibodies
Antibodies
Serum
Palivizumab
Respiratory Syncytial Virus Infections
British Columbia
Pharmacokinetics
Adaptive Immunity
additive effect
Canada
pharmacokinetics
Hospitalization
Assays
Guidelines

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Respiratory syncytial virus-neutralizing serum antibody titers in infants following palivizumab prophylaxis with an abbreviated dosing regimen. / Claydon, Jennifer; Sur, Amitava; Callejas, Allison; Ladd, Mihoko; Kwan, Eddie; Taylor, Richard; Turvey, Stuart E.; Solimano, Alfonso; Lavoie, Pascal M.; Marr, Nico.

In: PLoS One, Vol. 12, No. 4, e0176152, 01.04.2017.

Research output: Contribution to journalArticle

Claydon, J, Sur, A, Callejas, A, Ladd, M, Kwan, E, Taylor, R, Turvey, SE, Solimano, A, Lavoie, PM & Marr, N 2017, 'Respiratory syncytial virus-neutralizing serum antibody titers in infants following palivizumab prophylaxis with an abbreviated dosing regimen', PLoS One, vol. 12, no. 4, e0176152. https://doi.org/10.1371/journal.pone.0176152
Claydon, Jennifer ; Sur, Amitava ; Callejas, Allison ; Ladd, Mihoko ; Kwan, Eddie ; Taylor, Richard ; Turvey, Stuart E. ; Solimano, Alfonso ; Lavoie, Pascal M. ; Marr, Nico. / Respiratory syncytial virus-neutralizing serum antibody titers in infants following palivizumab prophylaxis with an abbreviated dosing regimen. In: PLoS One. 2017 ; Vol. 12, No. 4.
@article{944a7f5f61c34a4d89b825cfb71ca601,
title = "Respiratory syncytial virus-neutralizing serum antibody titers in infants following palivizumab prophylaxis with an abbreviated dosing regimen",
abstract = "Background Monthly injections of palivizumab during the respiratory syncytial virus (RSV) season in atrisk infants reduces RSV-associated hospitalizations. However, the additive effect of naturally acquired immunity remains unclear. The objective of this study was to assess total neutralizing serum antibodies (NAb) against RSV in at-risk infants who had received an abbreviated course of palivizumab prophylaxis. Methods Serum samples were collected from infants enrolled in the RSV Immunoprophylaxis Program in British Columbia, Canada over 2 consecutive RSV seasons (2013 to 2015). Infants in this program had received an abbreviated course of palivizumab in accordance with the provincial guidelines. Data were compared to adults and infants less than 12 months of age who did not receive palivizumab. Anti-RSV NAb titers were measured using an RSV microneutralization assay. Findings Infants who received palivizumab had anti-RSV NAb titers at the end of the RSV season that persisted beyond what is expected from the pharmacokinetics of palivizumab alone. Moreover, 54{\%} of the control infants who did not receive palivizumab and all tested adults had protective anti-RSV NAb titers.Conclusions Based on our observations, we hypothesize that naturally acquired NAb provide additive protection, which may significantly reduce the need for additional doses of palivizumab in infants at risk of severe RSV infections.",
author = "Jennifer Claydon and Amitava Sur and Allison Callejas and Mihoko Ladd and Eddie Kwan and Richard Taylor and Turvey, {Stuart E.} and Alfonso Solimano and Lavoie, {Pascal M.} and Nico Marr",
year = "2017",
month = "4",
day = "1",
doi = "10.1371/journal.pone.0176152",
language = "English",
volume = "12",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "4",

}

TY - JOUR

T1 - Respiratory syncytial virus-neutralizing serum antibody titers in infants following palivizumab prophylaxis with an abbreviated dosing regimen

AU - Claydon, Jennifer

AU - Sur, Amitava

AU - Callejas, Allison

AU - Ladd, Mihoko

AU - Kwan, Eddie

AU - Taylor, Richard

AU - Turvey, Stuart E.

AU - Solimano, Alfonso

AU - Lavoie, Pascal M.

AU - Marr, Nico

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Background Monthly injections of palivizumab during the respiratory syncytial virus (RSV) season in atrisk infants reduces RSV-associated hospitalizations. However, the additive effect of naturally acquired immunity remains unclear. The objective of this study was to assess total neutralizing serum antibodies (NAb) against RSV in at-risk infants who had received an abbreviated course of palivizumab prophylaxis. Methods Serum samples were collected from infants enrolled in the RSV Immunoprophylaxis Program in British Columbia, Canada over 2 consecutive RSV seasons (2013 to 2015). Infants in this program had received an abbreviated course of palivizumab in accordance with the provincial guidelines. Data were compared to adults and infants less than 12 months of age who did not receive palivizumab. Anti-RSV NAb titers were measured using an RSV microneutralization assay. Findings Infants who received palivizumab had anti-RSV NAb titers at the end of the RSV season that persisted beyond what is expected from the pharmacokinetics of palivizumab alone. Moreover, 54% of the control infants who did not receive palivizumab and all tested adults had protective anti-RSV NAb titers.Conclusions Based on our observations, we hypothesize that naturally acquired NAb provide additive protection, which may significantly reduce the need for additional doses of palivizumab in infants at risk of severe RSV infections.

AB - Background Monthly injections of palivizumab during the respiratory syncytial virus (RSV) season in atrisk infants reduces RSV-associated hospitalizations. However, the additive effect of naturally acquired immunity remains unclear. The objective of this study was to assess total neutralizing serum antibodies (NAb) against RSV in at-risk infants who had received an abbreviated course of palivizumab prophylaxis. Methods Serum samples were collected from infants enrolled in the RSV Immunoprophylaxis Program in British Columbia, Canada over 2 consecutive RSV seasons (2013 to 2015). Infants in this program had received an abbreviated course of palivizumab in accordance with the provincial guidelines. Data were compared to adults and infants less than 12 months of age who did not receive palivizumab. Anti-RSV NAb titers were measured using an RSV microneutralization assay. Findings Infants who received palivizumab had anti-RSV NAb titers at the end of the RSV season that persisted beyond what is expected from the pharmacokinetics of palivizumab alone. Moreover, 54% of the control infants who did not receive palivizumab and all tested adults had protective anti-RSV NAb titers.Conclusions Based on our observations, we hypothesize that naturally acquired NAb provide additive protection, which may significantly reduce the need for additional doses of palivizumab in infants at risk of severe RSV infections.

UR - http://www.scopus.com/inward/record.url?scp=85018532012&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018532012&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0176152

DO - 10.1371/journal.pone.0176152

M3 - Article

C2 - 28437470

AN - SCOPUS:85018532012

VL - 12

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 4

M1 - e0176152

ER -